Ambys Medicines is working to fundamentally transform the lives of people suffering from severe liver diseases by creating breakthrough therapies capable of restoring liver function, preventing the progression of liver disease, and treating the devastating complications of liver failure.We are pioneering multiple novel technologies — including liver cell therapy, liver reprogramming gene therapies, and liver-targeted drug therapies — to meet the urgent need for treatments that reverse disease progression across multiple liver diseases that are untreatable or poorly treated today.

HR and Recruiting project for life sciences companies.

HealthTell is an early stage Life Sciences company that utilizes an Immunosignature™ Technology for accurate and timely detection and monitoring of more than 30 progressive diseases. Based on robust, proprietary technology, the company is developing the first and only diagnostic platform capable of assessing an individual’s immune system response to specific diseases.Over ten years of scientific effort has demonstrated the power of the HealthTell Immunosignature technology across over 30 conditions, ranging from various cancers, infectious, auto and non-autoimmune diseases. Our goal is to provide the medical industry with a tool that will change the face of diagnostics; a simple, affordable, accurate diagnostic test.This disruptive technology enables physicians to detect the presence or absence of a disease in its earliest stage, improving patient outcomes and reducing healthcare expenditures. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage one’s health and make more informed decisions.Over 170 million people, in the US alone, are affected by neurological, autoimmune, oncologic, metabolic and infectious diseases. These diseases create significant economic burdens totaling over a trillion dollars. HealthTell will enable early detection of diseases, when behavioral and therapeutic interventions are most effective. This will result in saving millions of lives, while reducing healthcare economics.

At Twist Bioscience, our expertise is synthetic DNA. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. The Twist Bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. For more information, please visit www.twistbioscience.com

Auxogyn is dedicated to advancing women’s reproductive health through diagnostic technologies that generate information to be used by physicians and their patients in making treatment decisions. Our commitment is to instill clinical rigor and discipline to bring new innovation to market through science and technology. Through an inter-disciplinarian approach we take scientific discovery and develop a prognostic assay that is validated first through independent data followed by multiple-site study clinical validation. We pursue a regulatory path to assure our technologies are safe and effective and meet stringent regulatory standards.

Personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. Our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. Our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. We analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms.Personalis Genome Services provides a vertically integrated solution from NGS sequencing to interpretation with a focus on providing superior, highly accurate results to researchers and clinicians. Our services support researchers engaging in large case-control and family-based genome studies of complex or Mendelian diseases and traits, pharmacogenomics, and cancer.

StemCells, Inc. is applying its scientific and industry leadership in stem cell biology to discover, develop and commercialize breakthrough therapeutics and enabling tools and technologies for use in stem cell-based research and drug discovery.

The BHRN is a consortium of Human Resources professionals in the San Francisco Bay Area Biotech* community. Member communications and resources are coordinated via this forum. Monthly meetings are held at local sponsoring companies.